Hospital-related healthcare expenditure of impending versus completed pathological femur fractures: a propensity score matched study of 265 patients
DOI:
https://doi.org/10.2340/17453674.2025.43479Keywords:
Fractures, Metastatic bone disease, OncologyAbstract
Background and purpose: The prevalence of metastatic bone disease as well as the accompanying societal costs are expected to increase due to advances in cancer treatment. While the literature suggests that there is economic value in prophylactic stabilization compared with the fixation of completed pathological fractures in long bone metastases, studies are limited by their small sample sizes and insufficient correction for potential confounders. We aimed to evaluate whether prophylactic treatment of an impending femur fracture was associated with lower healthcare costs compared with completed pathologic fractures. We further aimed to compare prophylactic surgical treatment with completed pathological fractures in terms of postoperative complications, discharge disposition, and postoperative length of stay.
Methods: This is a retrospective cohort study with propensity score matching (PSM). We included clinical and financial data for 265 patients who received surgery for impending (n = 161) or completed (n = 104) femoral fractures of metastatic lesions, from 2 affiliated urban tertiary care centers between 2016 and 2020 in the United States. After PSM on 13 variables, including demographics and clinical characteristics, 100 impending fractures were matched with 100 completed fractures. The primary outcome was healthcare costs per episode of care, defined as the total cost from admission to 30 days after discharge.
Results: We found no difference in total cost of care between patients undergoing prophylactic surgical treatment and patients who underwent surgical treatment for a completed pathological fracture (median difference 44 cost-units [CU], 95% confidence interval [CI] –294 to 262). No differences were seen when dividing total cost into cost during hospital admission (median difference –25 CUs, CI –152 to 159) and 30 days following discharge (median difference 31 CUs, CI –74 to 88). Patients with completed pathologic fractures were more often discharged to rehabilitation facilities (57/100, vs 30/100, P < 0.01).
Conclusion: In contrast to earlier findings, we showed no difference in treatment costs between surgical management of impending and completed pathological fractures of femur metastases after adjusting for confounding factors. However, patients with completed pathological fractures were significantly more likely to require discharge to rehabilitation facilities, highlighting potential out-of-hospital costs related to extended rehabilitation, reduced mobility, and loss of independence.
Downloads
References
DiCaprio M R, Murtaza H, Palmer B, Evangelist M. Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease. Ann Joint 2022; 7: 28. doi: 10.21037/aoj-20-97. DOI: https://doi.org/10.21037/aoj-20-97
Coleman R E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-9s. doi: 10.1158/1078-0432.CCR-06-0931. DOI: https://doi.org/10.1158/1078-0432.CCR-06-0931
Groot O Q, Lans A, Twining P K, Bongers M E R, Kapoor N D, Verlaan J-J, et al. Clinical outcome differences in the treatment of impending versus completed pathological long-bone fractures. J Bone Joint Surg Am 2022; 104: 307-15. doi: 10.2106/JBJS.21.00711. DOI: https://doi.org/10.2106/JBJS.21.00711
Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res 2003: S4-13. doi: 10.1097/01.blo.0000093045.56370.dd. DOI: https://doi.org/10.1097/01.blo.0000093045.56370.dd
El Abiad J M, Raad M, Puvanesarajah V, Rao S S, Morris C D, Levin A S. Prophylactic versus postfracture stabilization for metastatic lesions of the long bones: a comparison of 30-day postoperative outcomes. J Am Acad Orthop Surg 2019; 27: e709-16. doi: 10.5435/JAAOS-D-18-00345. DOI: https://doi.org/10.5435/JAAOS-D-18-00345
Schulman K L, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007; 109: 2334-42. doi: 10.1002/cncr.22678. DOI: https://doi.org/10.1002/cncr.22678
Thio Q C B S, Goudriaan W A, Janssen S J, Paulino Pereira N R, Sciubba D M, Rosovksy R P, et al. Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. Br J Cancer 2018; 119: 737-43. doi: 10.1038/s41416-018-0231-6. DOI: https://doi.org/10.1038/s41416-018-0231-6
Janssen S J, van Dijke M, Lozano-Calderón S A, Ready J E, Raskin K A, Ferrone M L, et al. Complications after surgery for metastatic humeral lesions. J Shoulder Elbow Surg 2016; 25: 207-15. doi: 10.1016/j.jse.2015.08.009. DOI: https://doi.org/10.1016/j.jse.2015.08.009
Janssen S J, Kortlever J T P, Ready J E, Raskin K A, Ferrone M L, Hornicek F J, et al. Complications after surgical management of proximal femoral metastasis: a retrospective study of 417 patients. J Am Acad Orthop Surg 2016; 24: 483-94. doi: 10.5435/JAAOS-D-16-00043. DOI: https://doi.org/10.5435/JAAOS-D-16-00043
Andronis L, Goranitis I, Bayliss S, Duarte R. Cost-effectiveness of treatments for the management of bone metastases: a systematic literature review. PharmacoEconomics 2018; 36: 301-22. doi: 10.1007/s40273-017-0595-0. DOI: https://doi.org/10.1007/s40273-017-0595-0
Forsberg J A, Eberhardt J, Boland P J, Wedin R, Healey J H. Estimating survival in patients with operable skeletal metastases: an application of a Bayesian belief network. PloS One 2011; 6: e19956. doi: 10.1371/journal.pone.0019956. DOI: https://doi.org/10.1371/journal.pone.0019956
Willeumier J J, Linden Y M van der, Wal C W P G van der, Jutte P C, Velden J M van der, Smolle M A, et al. An easy-to-use prognostic model for survival estimation for patients with symptomatic long bone metastases. J Bone Joint Surg Am 2018; 100: 196-204. doi: 10.2106/JBJS.16.01514. DOI: https://doi.org/10.2106/JBJS.16.01514
Azam F, Latif M F, Farooq A, Tirmazy S H, AlShahrani S, Bashir S, et al. Performance status assessment by Using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol 2019; 12: 728-36. doi: 10.1159/000503095. DOI: https://doi.org/10.1159/000503095
Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83. doi: 10.1016/0021-9681(87)90171-8. DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Katagiri H, Okada R, Takagi T, Takahashi M, Murata H, Harada H, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 2014; 3: 1359-67. doi: 10.1002/cam4.292. DOI: https://doi.org/10.1002/cam4.292
Meissel K, Yao E. Using Cliff’s Delta as a non-parametric effect size measure: an accessible web app and R tutorial 2024. Available from: https://doi.org/10.7275/PARE.1977.
Nathan S S, Healey J H, Mellano D, Hoang B, Lewis I, Morris C D, et al. Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J Clin Oncol 2005; 23:6072-82. doi: 10.1200/JCO.2005.08.104. DOI: https://doi.org/10.1200/JCO.2005.08.104
Wang Y, Cai H, Li C, Jiang Z, Wang L, Song J, et al. Optimal caliper width for propensity score matching of three treatment groups: a Monte Carlo study. PLoS One 2013; 8: e81045. doi: 10.1371/journal.pone.0081045. DOI: https://doi.org/10.1371/journal.pone.0081045
Austin P C. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-58. doi: 10.1002/sim.5984. DOI: https://doi.org/10.1002/sim.5984
McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 1947; 12:153-7. doi: 10.1007/BF02295996. DOI: https://doi.org/10.1007/BF02295996
Stekhoven D J, Bühlmann P. MissForest-non-parametric missing value imputation for mixed-type data. Bioinformatics (Oxford, England) 2012; 28: 112-18. doi: 10.1093/bioinformatics/btr597. DOI: https://doi.org/10.1093/bioinformatics/btr597
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4. doi: 10.1001/jama.2013.281053. DOI: https://doi.org/10.1001/jama.2013.281053
Blank A T, Lerman D M, Patel N M, Rapp T B. Is prophylactic intervention more cost-effective than the treatment of pathologic fractures in metastatic bone disease? Clin Orthop Relat Res 2016; 474: 1563-70. doi: 10.1007/s11999-016-4739-x. DOI: https://doi.org/10.1007/s11999-016-4739-x
Mosher Z A, Patel H, Ewing M A, Niemeier T E, Hess M C, Wilkinson E B, et al. Early clinical and economic outcomes of prophylactic and acute pathologic fracture treatment. J Oncol Pract 2019; 15: e132-40. doi: 10.1200/JOP.18.00431. DOI: https://doi.org/10.1200/JOP.18.00431
Cecconi M, Hochrieser H, Chew M, Grocott M, Hoeft A, Hoste A, et al. Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery. Br J Anaesth 2016; 116: 63-9. doi: 10.1093/bja/aev373. DOI: https://doi.org/10.1093/bja/aev373
Sagi H C, Dziadosz D, Mir H, Virani N, Olson C. Obesity, leukocytosis, embolization, and injury severity increase the risk for deep postoperative wound infection after pelvic and acetabular surgery. J Orthop Trauma 2013; 27:6-10. doi: 10.1097/BOT.0b013e31825cf382. DOI: https://doi.org/10.1097/BOT.0b013e31825cf382
Wester C, Zhang T S, Harrington M A, Halawi M J. Sodium abnormalities are an independent predictor of complications in total joint arthroplasty: a cautionary tale! J Arthroplasty 2021; 36: 3859-63. doi: 10.1016/j.arth.2021.08.006. DOI: https://doi.org/10.1016/j.arth.2021.08.006
D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: pathogenesis and therapeutic options. J Bone Oncol 2019; 15:100205. doi: 10.1016/j.jbo.2018.10.004. DOI: https://doi.org/10.1016/j.jbo.2018.10.004
Damron T A, Morgan H, Prakash D, Grant W, Aronowitz J, Heiner J. Critical evaluation of Mirels rating system for impending pathologic fractures. Clin Orthop Relate Res 2003; 415: S201-7. doi: 10.1097/01.blo.0000093842.72468.73. DOI: https://doi.org/10.1097/01.blo.0000093842.72468.73
Herbst R S, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553:446-54. doi: 10.1038/nature25183. DOI: https://doi.org/10.1038/nature25183
Nevedomskaya E, Baumgart S J, Haendler B. Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 2018; 19: E1359. doi: 10.3390/ijms19051359. DOI: https://doi.org/10.3390/ijms19051359
Racine A M, Tommet D, D’Aquila M L, Fong T G, Gou Y, Tabloski P A, et al. Machine learning to develop and internally validate a predictive model for post-operative delirium in a prospective, observational clinical cohort study of older surgical patients. J Gen Intern Med 2021; 36: 265-73. doi: 10.1007/s11606-020-06238-7. DOI: https://doi.org/10.1007/s11606-020-06238-7
Ogink P T, Groot O Q, Karhade A V, Bongers M E R, Oner F C, Verlaan J-J, et al. Wide range of applications for machine-learning prediction models in orthopedic surgical outcome: a systematic review. Acta Orthop 2021; 92: 526-31. doi: 10.1080/17453674.2021.1932928. DOI: https://doi.org/10.1080/17453674.2021.1932928
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Tom M de Groot, Michelle R Shimizu, David Shin, Olivier Q Groot, Stein J Janssen, Kevin A Raskin, Eric T Newman, Marco L Ferrone, Santiago A Lozano-Calderon, Joseph H Schwab, Paul C Jutte
This work is licensed under a Creative Commons Attribution 4.0 International License.
